No profile data available.
ADC Therapeutics SA (ADCT) is a healthcare company in the blood cancer treatment drugs industry, based in Epalinges, Switzerland, with about 188 full-time employees.
It reported revenue of $81.36 million for fiscal year 2025, up 14.9% from fiscal year 2024, and net income of -$142.62 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $20.85 million, down 9.5% from a year before. United States was its largest region in fiscal year 2025, with 90% of revenue. Its market capitalization was $220.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. S.
ADC Therapeutics SA reported $81.36 million in revenue for fiscal year 2025, up 14.9% from $70.84 million in fiscal year 2024. In Q1 2026 revenue was $20.85 million.
United States: 90% of revenue by region in fiscal year 2025, followed by Europe, The Middle East and Africa (10%).
$220.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Corvus Pharmaceuticals, Inc. (CRVS), OmniAb, Inc. (OABI), Sellas Life Sciences Group, Inc. (SLS), Lyell Immunopharma, Inc. (LYEL).